PriceTargets.com logo

NYSEAMERICAN:HEB - Hemispherx BioPharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/31/1969 06:45 PM ET
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Hemispherx BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HEB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HEB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
This price target is based on 0 analysts offering 12 month price targets for Hemispherx BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
N/A
The current consensus among 0 investment analysts is to n/a stock in Hemispherx BioPharma. This rating has held steady since July 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
8/22/2019Maxim GroupDowngradeBuy ➝ Hold
i
Rating by Jason McCarthy at Maxim Group
8/21/2019Ascendiant Capital MarketsSet Price TargetBuy$6.00
i
Rating by Ed Woo at Ascendiant Capital Markets
8/9/2019Maxim GroupReiterated RatingBuy$8.00
i
Rating by Jason McCarthy at Maxim Group
6/14/2019Maxim GroupInitiated CoverageBuy$8.00
i
5/17/2019Ascendiant Capital MarketsSet Price TargetBuy$44.00
i
Rating by Ed Woo at Ascendiant Capital Markets
(Data available from 1/25/2016 forward)
Hemispherx BioPharma logo
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

14,900 shs

Average Volume

102,599 shs

Market Capitalization

$5.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hemispherx BioPharma?

The following Wall Street analysts have issued reports on Hemispherx BioPharma in the last twelve months:

What is the current price target for Hemispherx BioPharma?

0 Wall Street analysts have set twelve-month price targets for Hemispherx BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hemispherx BioPharma in the next year.

What is the current consensus analyst rating for Hemispherx BioPharma?

Hemispherx BioPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."

What other companies compete with Hemispherx BioPharma?

Other companies that are similar to Hemispherx BioPharma include Midatech Pharma plc (MTPH.L), Nuvo Pharmaceuticals Inc. (NRI.TO), Crescita Therapeutics Inc. (CTX.TO), ValiRx plc (VAL.L), Kane Biotech Inc. (KNE.V), Devonian Health Group Inc. (GSD.V), Realm Therapeutics, Nuformix plc (NFX.L), Pascal Biosciences Inc. (PAS.V), Naturally Splendid Enterprises Ltd. (NSP.V), Medicure Inc. (MPH.V), Bioasis Technologies Inc. (BTI.V), Ovoca Bio plc (OVB.L), Hemostemix Inc. (HEM.V) and Horizon Discovery Group plc (HZD.L).

How do I contact Hemispherx BioPharma's investor relations team?

Hemispherx BioPharma's physical mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company's listed phone number is +1-407-2718516. The official website for Hemispherx BioPharma is www.hemispherx.net.